The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite 5 hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.

The present invention relates to compositions comprising virus-like particles and microcrystalline tyrosine and its use for treating cancer.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which specific Interleukin-1 mutein antigens, IL-1-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against IL-1.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which preferably comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which specific feline Interleukin-1 mutein antigens, fIL-1-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against fIL-1.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which canine Interleukin-1 mutein antigens, cIL-1-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against cIL-1.

The present invention relates to veterinary compositions comprising NGF antigen linked to modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), in particular to modified VLPs of CMV comprising chimeric CMV polypeptides for use in a method of treating a NGF-related disorder in canine, in particular in the treatment of pain, such as for example pain associated with osteoarthritis (OA) in dogs